SGMOQ · Sangamo Therapeutics, Inc · Analyst Estimates
$0.15
+0.00 (+1.51%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”View the 10-Q filed May 14, 2026
Market Cap
$58.00M
Shares
414.29M
Volume · Oct 2
1.6M
Avg daily vol (3M)
2.74M
Analyst Estimates
Compare analyst forecasts for Sangamo Therapeutics, Inc across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 15:06 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.5
|
-0.03167
|
0.29
|
— |
-0.07
|
-0.07
|
-0.07
|
0.02
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
6
|
— | — | — | — |
1
|
1
|
2
|
0
|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
— | — | — | — | — | — | — | — |